Manufacturer of Controlled Substances; Notice of Application, 71558 [E5-6609]

Download as PDF 71558 Federal Register / Vol. 70, No. 228 / Tuesday, November 29, 2005 / Notices States International Trade Commission (Commission) determines, pursuant to section 751(b) of the Tariff Act of 1930 (19 U.S.C. 1675d(b)) (the Act), that revocation of the antidumping duty orders covering certain frozen warmwater shrimp and prawns from India and Thailand would be likely to lead to continuation or recurrence of material injury to an industry in the United States. Certain frozen warmwater shrimp and prawns from India and Thailand are provided for in subheadings 0306.13.00 and 1605.20.10 of the Harmonized Tariff Schedule of the United States. Background On December 17, 2004, the Department of Commerce determined that imports of certain frozen and canned warmwater shrimp and prawns from India and Thailand are being sold in the United States at less than fair value (LTFV) within the meaning of section 731 of the Act (19 U.S.C. 1673) (69 FR 76916, 76918, December 23, 2004); and on January 6, 2005 the Commission determined, pursuant to section 735(b)(1) of the Act (19 U.S.C. 1673d(b)(1)), that an industry in the United States was materially injured by reason of imports of such LTFV merchandise. Accordingly, Commerce ordered that antidumping duties be imposed on such imports (70 FR 5143, February 1, 2005). On January 6, 2005, when the Commission conducted its vote in the original investigations, it stated that it was concerned about the possible impact of the December 26, 2004, tsunami on the shrimp industries of India and Thailand. The tsunami occurred prior to the closing of the record in the original investigations on December 27, 2004. At the time the record closed, however, factual information as to any impact of the tsunami on the ability of producers in India or Thailand to produce and export shrimp was not available. On February 8, 2005, the Commission published a Federal Register notice (70 FR 6728) inviting comments from the public on whether changed circumstances exist sufficient to warrant the institution of changed circumstances reviews of the Commission’s affirmative determinations concerning certain frozen warmwater shrimp and prawns from India and Thailand. The Commission instituted the subject investigations (investigation Nos. 751–TA–28–29), effective May 5, 2005, after having reviewed the comments it received in response to that request, and having determined that it had received information which showed VerDate Aug<31>2005 20:13 Nov 28, 2005 Jkt 208001 changed circumstances sufficient to warrant instituting review investigations and that there was good cause for instituting such review investigations within two years after publication of the orders. Notice of the scheduling of the Commission’s investigations and of a public hearing to be held in connection therewith was given by posting copies of the notice in the Office of the Secretary, U.S. International Trade Commission, Washington, DC, and by publishing the notice in the Federal Register of May 5, 2005 (70 FR 23884). The hearing was held in Washington, DC, on September 14, 2005, and all persons who requested the opportunity were permitted to appear in person or by counsel. The Commission transmitted its determinations in these investigations to the Secretary of Commerce on November 21, 2005. The views of the Commission are contained in USITC Publication 3813 (November 2005), entitled Certain Frozen Warmwater Shrimp and Prawns from India and Thailand: Investigation Nos. 751–TA– 28–29. Issued: November 21, 2005. By order of the Commission. Marilyn R. Abbott, Secretary to the Commission. [FR Doc. E5–6593 Filed 11–28–05; 8:45 am] BILLING CODE 7020–02–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on March 3, 2005, American Radiolabeled Chemicals, Inc., 101 Arc Drive, St. Louis, Missouri 63146, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed in Schedules I and II: Drug Schedule Gamma hydroxybutyric acid (2010). Dimethyltryptamine (7435) ........... Dihydromorphine (9145) ............... Amphetamine (1100) .................... Methamphetamine (1105) ............ Lysergic acid diethylamide (7315). Phencyclidine (7471) .................... Phenylacetone (8501) .................. Cocaine (9041) ............................. Codeine (9050) ............................. Oxycodone (9143) ........................ PO 00000 Frm 00100 Fmt 4703 Sfmt 4703 I I I II II II II II II II II Drug Hydromorphone (9150) ................ Benzoylecgonine (9180) ............... Ecgonine (9180) ........................... Meperidine (9230) ........................ Metazocine (9240) ........................ Morphine (9300) ........................... Thebaine (9333) ........................... Oxymorphone (9652) ................... Schedule II II II II II II II II The company plans to manufacture in bulk, small quantities of the listed controlled substances as radiolabeled compounds. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail may be addressed, in quintuplicate, to the Acting Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL); or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no later than January 30, 2006. Joseph T. Rannazzisi, Acting Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E5–6609 Filed 11–28–05; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 6, 2005, Chemic Laboratories, Inc., 480 Neponset Street, Building 7C, Canton, Massachusetts 02021, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Cocaine (9041), a basic class of controlled substance listed in Schedule II. The company plans to manufacture small quantities of a cocaine derivative for distribution to its customers for the purpose of research. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance E:\FR\FM\29NON1.SGM 29NON1

Agencies

[Federal Register Volume 70, Number 228 (Tuesday, November 29, 2005)]
[Notices]
[Page 71558]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E5-6609]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on March 3, 2005, American 
Radiolabeled Chemicals, Inc., 101 Arc Drive, St. Louis, Missouri 63146, 
made application by renewal to the Drug Enforcement Administration 
(DEA) for registration as a bulk manufacturer of the basic classes of 
controlled substances listed in Schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Gamma hydroxybutyric acid (2010).             I
Dimethyltryptamine (7435)..................   I
Dihydromorphine (9145).....................   I
Amphetamine (1100).........................   II
Methamphetamine (1105).....................   II
Lysergic acid diethylamide (7315).            II
Phencyclidine (7471).......................   II
Phenylacetone (8501).......................   II
Cocaine (9041).............................   II
Codeine (9050).............................   II
Oxycodone (9143)...........................   II
Hydromorphone (9150).......................   II
Benzoylecgonine (9180).....................   II
Ecgonine (9180)............................   II
Meperidine (9230)..........................   II
Metazocine (9240)..........................   II
Morphine (9300)............................   II
Thebaine (9333)............................   II
Oxymorphone (9652).........................   II
------------------------------------------------------------------------

    The company plans to manufacture in bulk, small quantities of the 
listed controlled substances as radiolabeled compounds.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such a substance may file comments or 
objections to the issuance of the proposed registration pursuant to 21 
CFR 1301.33(a).
    Any such written comments or objections being sent via regular mail 
may be addressed, in quintuplicate, to the Acting Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration, Washington, DC 20537, Attention: DEA Federal Register 
Representative, Liaison and Policy Section (ODL); or any being sent via 
express mail should be sent to DEA Headquarters, Attention: DEA Federal 
Register Representative/ODL, 2401 Jefferson Davis Highway, Alexandria, 
Virginia 22301; and must be filed no later than January 30, 2006.

Joseph T. Rannazzisi,
Acting Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration.
[FR Doc. E5-6609 Filed 11-28-05; 8:45 am]
BILLING CODE 4410-09-P